Table 2.
Clinical data of subjects with T1D.
| T1D (n = 12) | ||
|---|---|---|
| Age at diabetes onset (years) |
5.3 (2.0) 5.6 (2.9; 8.7) |
|
| Diabetes duration (years) |
11.1 (2.0) 10.8 (8.0; 15.0) |
|
| Continuous glucose monitoring (n) | 12 | |
| Continuous subcutaneous insulin infusion pump (n) | 9 |
| HbA1c according to age | IFCC (mmol/mol) | NGSP (%) |
|---|---|---|
| Last HbA1c measurement |
53.3 (8.3) 52.0 (39.0; 67.0) |
7.0 (2.9) 6.9 (5.7; 8.3) |
| HbA1c, 0–8.9 years |
56.2 (7.2) 55.8 (44.7; 69.0) |
7.3 (2.8) 7.3 (6.2; 8.5) |
| HbA1c, 9.0–13.9 years |
56.6 (9.1) 55.6 (42.4; 77.7) |
7.3 (3.0) 7.2 (6.0; 9.3) |
| HbA1c, 14.0–17.9 years |
55.5 (9.7) 53.7 (38.1; 74.5) |
7.2 (3.0) 7.1 (5.6; 9.0) |
| HbA1c, 0–17.9 years |
56.1 (7.8) 56.1 (44.0; 73.4) |
7.3 (2.9) 7.3 (6.2; 8.9) |
Continuous glucose monitoring, real time or intermittent scanning. For continuous variables, mean (SD)/median (minimum; maximum) are presented.
HbA1c glycated hemoglobin A1c, IFCC International Federation of Clinical Chemistry, NGSP National Glycohemoglobin Standardization Program.